Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
Nirav N. Shah(Medical College of Wisconsin), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Marc Hoffmann(The University of Kansas Cancer Center), Jonathon B. Cohen(Emory University), Richard A. Walgren(Eli Lilly (United States)), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Minal Barve(Mary Crowley Cancer Research Center), Jennifer R. Brown(Dana-Farber Cancer Institute), Talha Munir(Leeds Teaching Hospitals NHS Trust), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Krish Patel, James N. Gerson(UPMC Hillman Cancer Center), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Katherine Bao(Loxo Oncology at Lilly (United States)), Hong‐Mei Han(Loxo Oncology at Lilly (United States)), Nicholas A. Cangemi(Loxo Oncology at Lilly (United States)), Toby A. Eyre(Oxford University Hospitals NHS Trust), Thomas Gastinne(Nantes Université), Meghan C. Thompson(Memorial Sloan Kettering Cancer Center), Chan Y. Cheah(The University of Western Australia), Jennifer Kherani(Peter MacCallum Cancer Centre), Chaitra S. Ujjani(Fred Hutch Cancer Center), Shuo Ma(Nantong University), Bita Fakhri(University of California, San Francisco), Alvaro J. Alencar(University of Miami), Paolo Ghia(Vita-Salute San Raffaele University), William G. Wierda(University of Maryland, Baltimore), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Michael Wang(St. Joseph Health System), Wojciech Jurczak(Jagiellonian University), Amy S. Ruppert(The University of Texas MD Anderson Cancer Center), Ian W. Flinn(Tennessee Oncology), Won-Seog Kim(Samsung Medical Center), Manish R. Patel(Sarah Cannon)
Cited by 4
Related Papers
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k